Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: Marty who wrote (275)	5/11/1998 10:19:00 PM
From: Gerald Underwood	Respond to of 705

Marty, Looks like NEO got a good plug today with Reuters at biz.yahoo.com Anytime a story gets picked up by a major newswire you will see broadened interest in the stock. IMO, this is what NEO needs. So many times one tends to feel that if I am aware of it, the street must be also. This is rarely the case. The broader the coverage, the more the interest. Reuters is certainly an improvement. Regards, Gerry

To: Marty who wrote (275)	5/16/1998 5:14:00 PM
From: Lee Fredrickson	Read Replies (3) \| Respond to of 705

Marty, Am addressing you, as your name was the 'oldest' I could find on the thread, (last June). I'll accept a response from anyone interested in NEOT. Have you ever gotten an E-response from NEOT to messages sent to their website? I E'd them last week, with a request for info about other drugs in their pipeline: Are they progressing?, Is work being done on any of them?, etc. So far no response. I stepped in lightly (all I can afford anyway), as the neuronal regeneration idea is just too revolutionary to pass up, and entering phase II could be a last chance at these kinds of prices. (Given the risks of getting a successful drug to marketability, these prices could also be a 104 week high.) Just wondering, do they answer their E-mail? Thx Lee